title: [GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
abstract: Thrombolytic therapy is an established strategy for the treatment of acute myocardial infarction. GPIIB/IIIA BLOCKERS + MODERN THROMBOLYTIC AGENTS: At present, the most attractive development for optimizing thrombolytic therapy includes the use of GPIIb/IIIa blockers in combination with modern thrombolytic agents such as alteplase and reteplase. The review summarizes the available results of clinical studies using standard doses of thrombolytic agents (TAMI 8, IMPACT-AMI, and PARADIGM) or reduced dosages of thrombolytic agents (TIMI 14 and SPEED) for combination therapy. The review also focuses on the implications of the combination therapy for coronary angioplasty immediately following coronary thrombolysis.
authors.affiliation: Abteilung Innere Medizin III (Schwerpunkt Kardiologie und Angiologie), Universitätsklinikum Freiburg. nordt@mm31.ukl.uni-freiburg.de
authors.forename: T K
authors.initials: TK
authors.lastname: Nordt
authors.forename: K
authors.initials: K
authors.lastname: Peter
authors.forename: C
authors.initials: C
authors.lastname: Bode
mesh_terms: D000077284:Abciximab; D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy*; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use; D014443:Tyrosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000085:Acetates; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D006493:Heparin; C084062:lamifiban; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D001241:Aspirin; D000077284:Abciximab